The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis
Open accessAbstract
Evasion of apoptosis is a hallmark of cancer, but the molecular circuitries of this process are not understood. Here we show that survivin, a member of the inhibitor of apoptosis gene family that is overexpressed in cancer, exists in a novel mitochondrial pool in tumor cells. In response to cell death stimulation, mitochondrial survivin is rapidly discharged in the cytosol, where it prevents caspase activation and inhibits apoptosis. Selective targeting of survivin to mitochondria enhances colony formation in soft agar, accelerates tumor growth in immunocompromised animals, and abolishes tumor cell apoptosis in vivo. Therefore, mitochondrial survivin orchestrates a novel pathway of apoptosis inhibition, which contributes to tumor progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536 · cited 1×
“Validating a cytoprotective mechanism of survivin has become a priority because of the dramatic exploitation of this pathway in human tumors (13), its frequent association with unfavorable disease outcome (14, 15), and the recent identification of molecular antagonists of survivin that are approaching clinical testing…”
BackgroundHengartner, M. O. (2000) · Nature · doi:10.1038/35037710 · Cited by 5,779
The Bcl2 family: regulators of the cellular life-or-death switch
Cory, S., & Adams, J. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc883 · Cited by 4,032 · cited 3×
“Treatment of mitochondrial pellets with proteinase K resulted in concentration-dependent loss of Bcl-2 (Figure 2A), which localizes to the outer mitochondrial membrane (3).”
BackgroundA novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma
Ambrosini, G., Adida, C., & Altieri, D. C. (1997) · Nature Medicine · doi:10.1038/nm0897-917 · Cited by 3,165
Self-citationMitochondrial control of cell death
Kroemer, G., & Reed, J. C. (2000) · Nature Medicine · doi:10.1038/74994 · Cited by 3,103
Two CD95 (APO‐1/Fas) signaling pathways
Scaffidi, C., Fulda, S., Srinivasan, A., Friesen, C., Li, F., Tomaselli, K. J., Debatin, K., Krammer, P. H., & Peter, M. E. (1998) · The EMBO Journal · doi:10.1093/emboj/17.6.1675 · Cited by 3,000
Proliferation, cell cycle and apoptosis in cancer
Evan, G. I., & Vousden, K. H. (2001) · Nature · doi:10.1038/35077213 · Cited by 2,724
(2001) · PubMed · Cited by 2,381
The β-Catenin/TCF-4 Complex Imposes a Crypt Progenitor Phenotype on Colorectal Cancer Cells
van de Wetering, M., Sancho, E., Verweij, C., de Lau, W., Oving, I., Hurlstone, A., van der Horn, K., Batlle, E., Coudreuse, D., Haramis, A.-P., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)01014-0 · Cited by 2,030
Cited by
Bonnet, S., Archer, S. L., Allalunis-Turner, J., Haromy, A., Beaulieu, C., Thompson, R., Lee, C. T., Lopaschuk, G. D., Puttagunta, L., Bonnet, S., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.10.020 · Cited by 1,530
Cancer despite immunosurveillance: immunoselection and immunosubversion
Zitvogel, L., Tesniere, A., & Kroemer, G. (2006) · Nature reviews. Immunology · doi:10.1038/nri1936 · Cited by 1,324
Survivin, cancer networks and pathway-directed drug discovery
Altieri, D. C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2293 · Cited by 994
Self-citationSurvivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics
Mita, A. C., Mita, M. M., Nawrocki, S. T., & Giles, F. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0746 · Cited by 765
Survivin, a cancer target with an emerging role in normal adult tissues
Fukuda, S., & Pelus, L. M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0375 · Cited by 465
Regulation of Tumor Cell Mitochondrial Homeostasis by an Organelle-Specific Hsp90 Chaperone Network
Kang, B. H., Plescia, J., Dohi, T., Rosa, J., Doxsey, S. J., & Altieri, D. C. (2007) · Cell · doi:10.1016/j.cell.2007.08.028 · Cited by 443
Self-citationSurvivin: a unique target for tumor therapy
Garg, H., Suri, P., Gupta, J. C., Talwar, G. P., & Dubey, S. (2016) · Cancer Cell International · doi:10.1186/s12935-016-0326-1 · Cited by 437
Survivin: A new target for anti-cancer therapy
Ryan, B. M., O’Donovan, N., & Duffy, M. J. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.05.003 · Cited by 379
Survivin and IAP proteins in cell-death mechanisms
Altieri, D. C. (2010) · Biochemical Journal · doi:10.1042/bj20100814 · Cited by 376
Self-citationMcMurtry, M. S. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23203 · Cited by 368
Rational design of shepherdin, a novel anticancer agent
Plescia, J., Salz, W., Xia, F., Pennati, M., Zaffaroni, N., Daidone, M. G., Meli, M., Dohi, T., Fortugno, P., Nefedova, Y., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.035 · Cited by 341
Self-citationWheatley, S. P., & Altieri, D. C. (2019) · Journal of Cell Science · doi:10.1242/jcs.223826 · Cited by 337
Self-citationHsp60 Regulation of Tumor Cell Apoptosis
Ghosh, J. C., Dohi, T., Kang, B. H., & Altieri, D. C. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m705904200 · Cited by 310
Self-citationThe case for survivin as a regulator of microtubule dynamics and cell-death decisions
Altieri, D. C. (2006) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2006.08.015 · Cited by 284
Self-citationOvercoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs)
Rathore, R., McCallum, J. E., Varghese, E., Florea, A.-M., & Büsselberg, D. (2017) · Apoptosis · doi:10.1007/s10495-017-1375-1 · Cited by 277
Nucleo-cytoplasmic transport as a therapeutic target of cancer
Gravina, G. L., Senapedis, W., McCauley, D., Baloglu, E., Shacham, S., & Festuccia, C. (2014) · Journal of Hematology & Oncology · doi:10.1186/s13045-014-0085-1 · Cited by 275
Survivin: A promising tumor biomarker
Duffy, M. J., O’Donovan, N., Brennan, D. J., Gallagher, W. M., & Ryan, B. M. (2007) · Cancer Letters · doi:10.1016/j.canlet.2006.12.020 · Cited by 267
Heat shock proteins and heat shock factor 1 in carcinogenesis and tumor development: an update
Ciocca, D. R., Arrigo, A. P., & Calderwood, S. K. (2013) · Archives of Toxicology · doi:10.1007/s00204-012-0918-z · Cited by 265
Survivin is released from cancer cells via exosomes
Khan, S., Jutzy, J. M. S., Aspe, J. R., McGregor, D. W., Neidigh, J. W., & Wall, N. R. (2011) · Apoptosis · doi:10.1007/s10495-010-0534-4 · Cited by 265
Self-citationBroekgaarden, M., Weijer, R., van Gulik, T. M., Hamblin, M. R., & Heger, M. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-015-9588-7 · Cited by 255
ATG5 is induced by DNA-damaging agents and promotes mitotic catastrophe independent of autophagy
Maskey, D., Yousefi, S., Schmid, I., Zlobec, I., Perren, A., Friis, R., & Simon, H.-U. (2013) · Nature Communications · doi:10.1038/ncomms3130 · Cited by 144
Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells
Tian, Z., Zhao, J.-J., Tai, Y.-T., Amin, S. B., Hu, Y., Berger, A. J., Richardson, P., Chauhan, D., & Anderson, K. C. (2012) · Blood · doi:10.1182/blood-2012-01-401794 · Cited by 82
p21 does not protect cancer cells from apoptosis induced by nongenotoxic p53 activation
Xia, M., Knezevic, D., & Vassilev, L. T. (2011) · Oncogene · doi:10.1038/onc.2010.413 · Cited by 64
Dohi, T., Salz, W., Costa, M., Ariyan, C., Basadonna, G. P., & Altieri, D. C. (2006) · The EMBO Reports · doi:10.1038/sj.embor.7400640 · Cited by 32
Self-citation
Metadata
- Authors
- Dohi, T., Beltrami, E., Wall, N. R., Plescia, J., & Altieri, D. C.
- Venue
- Journal of Clinical Investigation
- Published
- 2004-10-15
- Volume
- 114
- Issue
- 8
- Pages
- 1117-1127
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2170785948
- Cited by
- 405
- References
- 39
- FWCI
- 7.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.